Trial Profile
A Phase 2 Randomized, Double Blinded, Placebo Controlled Study of Oral Favipiravir Compared to Standard Supportive Care in Subjects With Mild or Asymptomatic COVID-19
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 Apr 2022
Price :
$35
*
At a glance
- Drugs Favipiravir (Primary)
- Indications COVID-19 respiratory infection
- Focus Therapeutic Use
- 12 Apr 2022 Results published in the Clinical Infectious Diseases
- 19 Apr 2021 Status changed from active, no longer recruiting to completed.
- 26 Mar 2021 Planned End Date changed from 1 Jul 2021 to 1 Apr 2021.